Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Significant Drop in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 12,600 shares, a decrease of 40.0% from the February 13th total of 21,000 shares. Based on an average trading volume of 81,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Atria Investments Inc purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at $122,000. Centaurus Financial Inc. raised its position in shares of Global X Genomics & Biotechnology ETF by 7.0% during the 3rd quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock valued at $169,000 after buying an additional 985 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at $205,000. Flow Traders U.S. LLC purchased a new position in Global X Genomics & Biotechnology ETF in the 3rd quarter worth $936,000. Finally, Oxinas Partners Wealth Management LLC purchased a new position in Global X Genomics & Biotechnology ETF in the 4th quarter worth $103,000. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Stock Up 1.1 %

Global X Genomics & Biotechnology ETF stock opened at $8.84 on Monday. Global X Genomics & Biotechnology ETF has a twelve month low of $8.59 and a twelve month high of $11.88. The firm has a 50 day moving average price of $9.69 and a 200-day moving average price of $10.31. The company has a market capitalization of $61.61 million, a P/E ratio of -3.78 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.